Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	17 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1612.50	1930.16	-	19.70	buy	pdf Detailed Estimates
	28 May 2023	Sun Pharmaceutical	Prabhudas Lilladhar Target	1612.50	1140.00	969.90 (66.25%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	ICICI Direct Target	1612.50	1140.00	969.90 (66.25%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1612.50	1160.00	969.90 (66.25%)	Target met	Buy	pdf post cache	Broker Report Specialty portfolio is amplifying margins ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q4FY23 performance was decent, aided by traction in specialty portfolio, India branded and launch of Revlimid in the US. Specialty business sales contribution had increased to 16.6% in FY23 (14% in FY22) and key assets like Ilumya, Winlevi and Cequa will likely improve the share to 21% by FY25E. pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	Motilal Oswal Target	1612.50	1160.00	969.90 (66.25%)	Target met	Buy	pdf post cache	Broker Report US/EM/ROW drive earnings for the quarter Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2023	Sun Pharmaceutical	ICICI Securities Limited Target	1612.50	1001.00	1034.50 (55.87%)	Target met	Hold	pdf post cache	Broker Report In-line performance; valuations fair ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q3FY23 performance was largely in line with our estimates. Consolidated revenue grew 12.9% YoY to Rs111.4bn (I-Sec: Rs110.5bn) driven by US and emerging market sales. EBITDA margin stood at 26.0% (I-Sec: 26.6%). Specialty portfolio grew 10.7% QoQ to US$223mn (ex- milestone income) led by growth in Ilumya and Winlevi. pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2023	Sun Pharmaceutical	ICICI Direct Target	1612.50	1210.00	1014.90 (58.88%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2023	Sun Pharmaceutical	Motilal Oswal Target	1612.50	1220.00	1034.50 (55.87%)	Target met	Buy	pdf post cache	Broker Report Specialty sales remains encouraging Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	19 Jan 2023	Sun Pharmaceutical	Motilal Oswal Target	1612.50	1200.00	1040.55 (54.97%)	Target met	Buy	pdf post cache	Broker Report Concert deal paves way to add JAK inhibitors to specialty portfolio Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	10 Nov 2022	Sun Pharmaceutical	Geojit BNP Paribas Reco Target	1612.50	1078.00	1013.55 (59.09%)	Target met	Hold	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	03 Nov 2022	Sun Pharmaceutical	SMC online	1612.50		1039.90 (55.06%)		Results Update	pdf post cache	Broker Report Sun Pharmaceuticals Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 27.15% from the last price of 1612.50. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

SUN PHARMACEUTICAL I

Sun Pharma

Specialty portfolio is amplifying margins

US/EM/ROW drive earnings for the quarter

In-line performance; valuations fair

Sun Pharma

Specialty sales remains encouraging

Concert deal paves way to add JAK inhibitors to specialty portfolio

SUN PHARMA

Sun Pharmaceuticals Industries

Advisor Screeners